{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:24:41Z","timestamp":1786926281257,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020439","name":"Jiangsu Pharmaceutical Association","doi-asserted-by":"crossref","award":["A202428"],"award-info":[{"award-number":["A202428"]}],"id":[{"id":"10.13039\/100020439","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Scientific Research Foundation","award":["YWJKJJHKYJJ-TYU066D"],"award-info":[{"award-number":["YWJKJJHKYJJ-TYU066D"]}]},{"name":"Suzhou Health Workforce Program","award":["GSWS2022040"],"award-info":[{"award-number":["GSWS2022040"]}]},{"name":"Discipline Promotion Program of the Second Affiliated Hospital of Soochow University","award":["XKTJ-XK202406"],"award-info":[{"award-number":["XKTJ-XK202406"]}]},{"name":"Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs","award":["2023TP1013"],"award-info":[{"award-number":["2023TP1013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01162-8","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:36:36Z","timestamp":1780997796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and application of a simple LC-MS\/MS method for therapeutic drug monitoring to guide colistin dosing in critically Ill patients"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4955-0859","authenticated-orcid":false,"given":"Yueyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinYun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3390\/molecules29132969","volume":"29","author":"E Diani","year":"2024","unstructured":"Diani E, Bianco G, Gatti M, Gibellini D, Gaibani P. Colistin: Lights and Shadows of an Older Antibiotic. Molecules. 2024;29:2969. https:\/\/doi.org\/10.3390\/molecules29132969.","journal-title":"Molecules"},{"key":"1162_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/microorganisms9020442","volume":"9","author":"M Hamel","year":"2021","unstructured":"Hamel M, Rolain JM, Baron SA. The History of Colistin Resistance Mechanisms in Bacteria: Progress and Challenges. Microorganisms. 2021;9:442. https:\/\/doi.org\/10.3390\/microorganisms9020442.","journal-title":"Microorganisms"},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","volume":"30","author":"LM Lim","year":"2010","unstructured":"Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB, Tsuji BT. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30:1279\u201391. https:\/\/doi.org\/10.1592\/phco.30.12.1279.","journal-title":"Pharmacotherapy"},{"key":"1162_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","volume":"6","author":"J Li","year":"2006","unstructured":"Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589\u2013601. https:\/\/doi.org\/10.1016\/S1473-3099(06)70580-1.","journal-title":"Lancet Infect Dis"},{"key":"1162_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","volume":"22","author":"RL Nation","year":"2009","unstructured":"Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22:535\u201343. https:\/\/doi.org\/10.1097\/QCO.0b013e328332e672.","journal-title":"Curr Opin Infect Dis"},{"key":"1162_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jssc.201000680","volume":"34","author":"Y Dotsikas","year":"2011","unstructured":"Dotsikas Y, Markopoulou CK, Koundourellis JE, Loukas YL. Validation of a novel LC-MS\/MS method for the quantitation of colistin A and B in human plasma. J Sep Sci. 2011;34:37\u201345. https:\/\/doi.org\/10.1002\/jssc.201000680.","journal-title":"J Sep Sci"},{"key":"1162_CR7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","volume":"71","author":"A Ordooei Javan","year":"2015","unstructured":"Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71:801\u201310. https:\/\/doi.org\/10.1007\/s00228-015-1865-4.","journal-title":"Eur J Clin Pharmacol"},{"key":"1162_CR8","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/cc3995","volume":"10","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27. https:\/\/doi.org\/10.1186\/cc3995.","journal-title":"Crit Care"},{"key":"1162_CR9","doi-asserted-by":"publisher","first-page":"e02319","DOI":"10.1128\/AAC.02319-16","volume":"61","author":"AP Zavascki","year":"2017","unstructured":"Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61:e02319\u201316. https:\/\/doi.org\/10.1128\/AAC.02319-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"1162_CR10","doi-asserted-by":"publisher","first-page":"107035","DOI":"10.1016\/j.ijantimicag.2023.107035","volume":"63","author":"FN Ball\u0131","year":"2024","unstructured":"Ball\u0131 FN, Ekinci PB, Kurtaran M, Kara E, Dizman GT, S\u00f6nmezer M\u00c7, Hayran M, Demirkan K, Metan G. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin. Int J Antimicrob Agents. 2024;63:107035. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107035.","journal-title":"Int J Antimicrob Agents"},{"key":"1162_CR11","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/cid\/civ723","volume":"61","author":"JM Pogue","year":"2015","unstructured":"Pogue JM, Ortwine JK, Kaye KS. Optimal Usage of Colistin: Are We Any Closer? Clin Infect Dis. 2015;61:1778\u201380. https:\/\/doi.org\/10.1093\/cid\/civ723.","journal-title":"Clin Infect Dis"},{"key":"1162_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1469-0691.2011.03667.x","volume":"18","author":"W Couet","year":"2012","unstructured":"Couet W, Gr\u00e9goire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect. 2012;18:30\u20139. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03667.x.","journal-title":"Clin Microbiol Infect"},{"key":"1162_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1471-2334-13-380","volume":"13","author":"L Sorl\u00ed","year":"2013","unstructured":"Sorl\u00ed L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380. https:\/\/doi.org\/10.1186\/1471-2334-13-380.","journal-title":"BMC Infect Dis"},{"key":"1162_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127\u201353. https:\/\/doi.org\/10.1007\/s00134-020-06050-1."},{"key":"1162_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jpba.2016.02.045","volume":"124","author":"M Zhao","year":"2016","unstructured":"Zhao M, Wu XJ, Fan YX, Guo BN, Zhang J. Development and validation of a UHPLC-MS\/MS assay for colistin methanesulphonate (CMS) and colistin in human plasma and urine using weak-cation exchange solid-phase extraction. J Pharm Biomed Anal. 2016;124:303\u20138. https:\/\/doi.org\/10.1016\/j.jpba.2016.02.045.","journal-title":"J Pharm Biomed Anal"},{"key":"1162_CR16","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline: bioanalytical method validation and study sample analysis (M10). 2022;1\u201359. https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf"},{"key":"1162_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ijantimicag.2017.12.025","volume":"51","author":"M Zhao","year":"2018","unstructured":"Zhao M, Wu XJ, Fan YX, Zhang YY, Guo BN, Yu JC, Cao GY, Chen YC, Wu JF, Shi YG, Li J, Zhang J. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. Int J Antimicrob Agents. 2018;51:714\u201320. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.12.025.","journal-title":"Int J Antimicrob Agents"},{"key":"1162_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jpba.2018.11.044","volume":"164","author":"I Dagla","year":"2019","unstructured":"Dagla I, Karkoula E, Baira E, Tsarbopoulos A, Gikas E. Analytical methodologies used for the determination of colistin in biological fluids. Is it still a challenge? J Pharm Biomed Anal. 2019;164:777\u201388. https:\/\/doi.org\/10.1016\/j.jpba.2018.11.044.","journal-title":"J Pharm Biomed Anal"},{"key":"1162_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jpba.2008.12.016","volume":"49","author":"B Jansson","year":"2009","unstructured":"Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC\/MS\/MS. Journal of pharmaceutical and biomedical analysis. J Pharm Biomed Anal. 2009;49:760\u20137. https:\/\/doi.org\/10.1016\/j.jpba.2008.12.016.","journal-title":"J Pharm Biomed Anal"},{"key":"1162_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jiph.2024.03.021","volume":"17","author":"JY Son","year":"2024","unstructured":"Son JY, Kim S, Porsuk T, Shin S, Choi YJ. Clinical outcomes of colistin methanesulfonate sodium in correlation with pharmacokinetic parameters in critically ill patients with multi-drug resistant bacteria-mediated infection: A systematic review and meta-analysis. J Infect Public Health. 2024;17:843\u201353. https:\/\/doi.org\/10.1016\/j.jiph.2024.03.021.","journal-title":"J Infect Public Health"},{"key":"1162_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10\u201339. https:\/\/doi.org\/10.1002\/phar.2209.","journal-title":"Pharmacotherapy"},{"key":"1162_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/antibiotics13030287","volume":"13","author":"W Katip","year":"2024","unstructured":"Katip W, Rayanakorn A, Sornsuvit C, Wientong P, Oberdorfer P, Taruangsri P, Nampuan T. High-Loading-Dose Colistin with Nebulized Administration for Carbapenem-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients: A Retrospective Cohort Study. Antibiotics. 2024;13:287. https:\/\/doi.org\/10.3390\/antibiotics13030287.","journal-title":"Antibiotics"},{"key":"1162_CR23","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiph.2023.05.024","volume":"16","author":"W Katip","year":"2023","unstructured":"Katip W, Rayanakorn A, Oberdorfer P, Taruangsri P, Nampuan T. Short versus Long Course of Colistin Treatment for Carbapenem-Resistant A. baumannii in Critically Ill Patients: A Propensity Score Matching Study. J Infect Public Health. 2023;16:1249\u201355. https:\/\/doi.org\/10.1016\/j.jiph.2023.05.024.","journal-title":"J Infect Public Health"},{"key":"1162_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/pharmaceutics14010031","volume":"14","author":"W Katip","year":"2021","unstructured":"Katip W, Oberdorfer P, Tawanwongsri W, Nampuan T. Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients. Pharmaceutics. 2021;14:31. https:\/\/doi.org\/10.3390\/pharmaceutics14010031.","journal-title":"Pharmaceutics"},{"key":"1162_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jpba.2019.03.023","volume":"170","author":"S Barco","year":"2019","unstructured":"Barco S, Castagnola E, Mesini A, Tripodi G, Cangemi G. Potential Pitfalls in LC\u2013MS\/MS Quantification of Colistin for Therapeutic Drug Monitoring of Patients Treated with Colistimethate. J Pharm Biomed Anal. 2019;170:193\u20135. https:\/\/doi.org\/10.1016\/j.jpba.2019.03.023.","journal-title":"J Pharm Biomed Anal"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01162-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01162-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01162-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:31:48Z","timestamp":1786923108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01162-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01162-8","relation":{"references":[{"id-type":"doi","id":"10.1007\/s00134-020-06050-1","asserted-by":"subject"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University (Approval number: JD-LK2024171-IR01). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants or their legal guardians, as required by the approved protocol (Informed consent form version 3.0, dated 10 April 2025).","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"109"}}